SLN Silence Therapeutics Corp: Rasio rega marang prakiraan pendapatan
Silence Therapeutics minimizes technological risks through large-scale contracts with global corporations in the siRNA therapy sector. The change in the forward P/S reflects current valuation dynamics, where the parameter is 2672.40. Financial stability is ensured by regular royalties from pharma behemoths. Market capitalization growth is driven by the success of zerlasiran and the platform's potential in treating rare pathologies.
SLN (Silence Therapeutics plc): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Silence Therapeutics|SLN - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas silence-therapeutics.com|SLN - Gunggung utang perusahaan|Utang marang nilai buku Silence Therapeutics Corp|SLN - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Silence Therapeutics|Rasio cepet silence-therapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
SLN - Penghasilan resik|Bathi sing dikarepake Silence Therapeutics|SLN - Periode bali modal bisnis|Rega marang bathi mangsa ngarep silence-therapeutics.com|SLN - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Silence Therapeutics plc|SLN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Silence Therapeutics|SLN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan silence-therapeutics.com|SLN - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Silence Therapeutics
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Silence Therapeutics plc (SLN)
For Silence Therapeutics (SLN), which develops high-precision RNA technologies for treating hematological pathologies, the forward P/S ratio reflects the company's market value relative to expected revenue. Analyzing this chart, an investor compares current brand capitalization costs with projected earnings to determine whether the business valuation is fair or if the asset is subject to speculative overheating.
Perusahaan pesaing
Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|intelliatx.com - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke STOK|biolifesolutions.com (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|Multiplikator forward rega marang pendapatan Sionna Therapeutics, Inc. (SION)|Multiplikator forward rega marang pendapatan PRME (Prime Medicine Bio)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha|uniQure Pharma - Multiplikator forward rega marang pendapatan|MeiraGTx Holdings plc - Rasio rega marang prakiraan pendapatan|regenxbio.com - Multiplikator Forward P/S|Solid Bio (SLDB) - Multiplikator forward rega marang pendapatan|OCGN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan DSGN (Design Therapeutics)|Multiplikator Forward P/S RCKT|Rasio rega marang prakiraan pendapatan FDMT (4D Molecular Therapeutics Inc)|Multiplikator Forward P/S LXEO (Lexeo Therapeutics Inc.)|Rega forward marang dodolan KRRO|EDIT - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.
